脂微球前列地尔联合依达拉奉治疗急性脑梗死疗效探讨

Influence of lipid microsphere alprostadil combined with edaravone onneurological function and serum S100B level of acute ischemic stroke patients

目的探讨脂微球前列地尔联合依达拉奉治疗急性脑梗死的疗效。方法选择2014-06至2016-06住院急性脑梗死患者60例,随机分为联合组(脂微球前列地尔+依达拉奉)和对照组(单用依达拉奉),各30例,全部患者于治疗前、治疗第3天、第7天和第14天行NIHSS评分并检测血清S100B蛋白水平。比较两组患者不同时段NIHSS评分及血清S100B蛋白水平变化。结果治疗后第3天、第7天和第14天联合组NIHSS评分及血清S100B蛋白水平均较对照组为低,差异有统计学意义(P<0.01)。对照组2例为进展性脑梗死,无一例不良反应;联合组1例为进展性脑梗死,2例出现头痛,1例出现面红,轻微肿胀感,未影响治疗。结论脂微球前列地尔联合依达拉奉治疗可改善急性脑梗死患者的临床疗效,减轻脑损伤程度。

Objective To investigate the influence of lipid microsphere alprostadil combined with edaravone on the neurologi- cal function and serum SIOOB level of patients with acute cerebral infarction. Methods Between June 2014 and June 2016, sixty patients with acute cerebral infarction were enrolled and randomly and equally divided into the combined group （lipid microsphere alprostadil and edaravone） and the control group （edaravone alone）. All the patients received brain MRI examinations（DWI） before treatment, and NIHSS and serum S100B tests before treatment as well as at day 3, 7 and 14 during treatment. The changes of NIHSS and serum S100B levels were compared between the two groups at different time points. Results NIHSS and serum S100B levels of the combined group at day 3,7 and 14 during treatment were significantly lower than those of the control group（ P 〈 0.01 ）. There were two cases of disease progression in the control group, but with no cases of adverse reactions. In the combined group, there was one case of progression, two cases of headache, and one patient who appeared red-faced and felt slightly swollen. Conclusions Lipid microsphere alprostadil combined with edaravone can improve clinical efficacy and alleviate brain damage in patients with acute ischemic stroke.